Antibody-drug conjugates are one of the most active areas of biopharma research and investment for developers and contract manufacturing firms alike. In this section we will collate our coverage of this exciting market.
22-Mar-2017 - Contract manufacturer Goodwin Biotechnology will work with Minneapolis Medical Research Foundation (MMRF) to develop vaccines to treat opioid addiction.
07-Mar-2017 - The US FDA has cleared Seattle Genetics to restart trials of its blood cancer candidate vadastuximab talirine that were halted last year after patient deaths.
24-Feb-2017 - LegoChem Biosciences has teamed up with Novimmune to develop and test antibody drug conjugate (ADC) drug.
01-Feb-2017 - Pfizer has resubmitted its antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) for regulatory review almost seven years after withdrawing it from the market.
27-Jan-2017 - Shark antibodies are an attractive way to deliver biologics to the brain, says Ossianix which is using its blood-brain barrier (BBB) crossing technology in collaboration with Lundbeck.
12-Oct-2016 - Catalent will continue to develop and manufacture a non-Hodgkin’s Lymphoma antibody-drug conjugate (ADC) for Triphase Accelerator Corporation after licensing out the candidate.
18-Aug-2016 - The acquisition of Ash Stevens and a US high potent API facility will bolster Piramal’s antibody-drug conjugate offerings, the Indian CDMO says.
14-Jun-2016 - Differentiated technologies buoyed by the recent $600m conjugation deal with Roche is driving Catalent’s biologics business, the firm told Biopharma-Reporter at BIO.
29-Apr-2016 - AbbVie has added the late-stage antibody-drug conjugate (ADC) Rova-T to its pipeline through the $5.8bn acquisition of Stemcentrx.
27-Apr-2016 - Three deals in the last week signal AbbVie’s strategy in immuno-oncology but are just the latest examples of Big Biopharma’s trend for clinical partnerships.
20-Apr-2016 - Triazamacrocyclic lipid complexes increase the efficiency of antibody-drug conjugates (ADCs) by delivering the payload right into the heart of a cancer cell, says BioCellChallenge.
19-Jan-2016 - Pfizer has invested $46m in separate collaborations with four R&D companies specialising in developing ADCs, immuno-oncology candidates and gene-therapies.
08-Dec-2015 - Pfizer and Bioatla have licensed each other’s technology platforms to develop ADCs with Conditionally Active Biologic (CAB) antibodies as the payload delivery vehicles.
24-Nov-2015 - Abzena is set to buy The Chemistry Research Solution (TCRS) in a deal one analyst says shows the firm’s intentions to dominate the bio-conjugation space.
21-Oct-2015 - Piramal chief executive Vivek Sharma won last week’s CPhI award for the pharma industry’s CEO of the year. Outsourcing-Pharma.com spoke to Sharma about his plans for the CDMO the day...
16-Oct-2015 - CDMO Ajinomoto Althea is opening a new facility to offer outsourced ADC (antibody drug conjugate) and HPAPI (highly potent active pharmaceutical ingredient) manufacturing, the Californian company has announced.
09-Oct-2015 - UK-based processing tech provider ADC Biotechnology will build a $10m plant for the GMP manufacture of antibody-drug conjugates (ADCs).
08-Sep-2015 - A bispecific antibody developed by Roche subsidiary Chugai has been granted Breakthrough Therapy Designation by the US FDA for the treatment of haemophilia A.
11-Aug-2015 - French firm MedinCell and Dutch company Corbion have formed a JV to produce polymers for unusual drug delivery of large and small molecule drugs.
30-Jun-2015 - Novasep is investing €10m ($11m) in a bio-conjugation plant it says will offer drugmakers a more complete antibody-drug conjugation (ADC) service.
02-Jun-2015 - University of Oxford scientists are saving undeliverable drugs by placing them in gas bubbles for better bioavailability and fewer side effects.
29-May-2015 - Innovate UK has awarded Crescendo Biologics a grant to fund development of drugs combining cytotoxic small molecule payloads with antibody fragments known as Humabodies.
22-May-2015 - A consortium including WuXi PharmaTech has agreed to acquire biotech client Ambrx for its antibody-drug conjugate (ADC) conjugation technology.
19-May-2015 - Almac is coupling tiny shark proteins to a cancer-killing warhead to develop an oncology drug, saying their small size makes for easy conjugation.
25-Mar-2015 - Takeda has licensed technology from ImmunoGen to make two antibody drug conjugates (ADCs) targeting cancer.